Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079508 · ClinicalTrials.gov registry record · Phase 3
Angiomax in Patients With HIT/HITTS Type II Undergoing CPB
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT00079508 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 125 participants.
The verdict
NCT00079508, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and effective anticoagulant.
Interventions
- DRUG Angiomax (bivalirudin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2004-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079508
The ClinicalTrials.gov registry entry for NCT00079508 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Angiomax (bivalirudin) is the first listed.
NCT00079508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079508 about?
NCT00079508 is a clinical study titled "Angiomax in Patients With HIT/HITTS Type II Undergoing CPB". The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and effective anticoagulant.
What is the current status of trial NCT00079508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2004-04.
What interventions are being tested in trial NCT00079508?
The interventions under investigation include: Angiomax (bivalirudin) (DRUG).
Who is sponsoring clinical trial NCT00079508?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.